Author

L. Thackray

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

J. E. Crowe· 3 shared P. Gilchuk· 3 shared R. H. Carnahan· 3 shared B. Doranz· 2 shared E. Binshtein· 2 shared E. C. Chen· 2 shared E. Davidson· 2 shared L. VanBlargan· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. E. Crowe

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

T. L. Darling, B. Ying, B. Whitener, L. VanBlargan, T. L. Bricker, C.-Y. Liang, A. Joshi, G. Bamunuarachchi, K. Seehra, A. Schmitz, P. Halfmann, Y. Kawaoka, S. Elbashir, D. K. Edwards, L. Thackray, , A. Boon

This study evaluates the efficacy of mRNA-1273 and Ad26.COV2.S vaccines against the B.1.621 variant in mice and hamsters, showing protection against infection and pathology.

bioRxiv · Dec 29, 2021Microbiology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein

N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe

The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.

bioRxiv · Jan 19, 2021Immunology

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

bioRxiv · May 12, 2020Immunology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

bioRxiv · May 12, 2020Immunology